Consonance Capital Management LP Trimmed Its Corcept Therapeutics INC (CORT) Position as Stock Price Rose

January 21, 2018 - By Ellis Scott

Investors sentiment decreased to 1.96 in 2017 Q3. Its down 0.47, from 2.43 in 2017Q2. It fall, as 13 investors sold CORT shares while 39 reduced holdings. 47 funds opened positions while 55 raised stakes. 71.96 million shares or 6.38% more from 67.64 million shares in 2017Q2 were reported. Renaissance Tech Ltd Com accumulated 0.08% or 3.67 million shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Mgmt accumulated 0% or 22,700 shares. Rhumbline Advisers holds 89,357 shares. Raymond James And holds 0% or 94,748 shares. Shaker Investments Ltd Liability Corporation Oh owns 114,085 shares. Sand Hill Global Advsrs Lc reported 10,000 shares. New York-based Gotham Asset has invested 0.02% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Fmr Ltd Limited Liability Company holds 0% or 353,395 shares in its portfolio. Citadel Lc has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). State Board Of Administration Of Florida Retirement Sys owns 44,813 shares for 0% of their portfolio. Ami Asset Mgmt Corporation holds 0.72% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 527,515 shares. Globeflex Cap Lp reported 1.39% stake. Tiaa Cref Mngmt Ltd Com, New York-based fund reported 547,610 shares. American Century Companies stated it has 139,360 shares. Principal Financial Grp Inc holds 38,692 shares or 0% of its portfolio.

Since December 8, 2017, it had 0 insider purchases, and 2 sales for $283,125 activity.

Mitchell Blutt decreased its stake in Corcept Therapeutics Inc (CORT) by 33.12% based on its latest 2017Q3 regulatory filing with the SEC. Consonance Capital Management Lp sold 1.92M shares as the company’s stock rose 42.01% with the market. The hedge fund run by Mitchell Blutt held 3.88 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $74.93M, down from 5.80 million at the end of the previous reported quarter. Consonance Capital Management Lp who had been investing in Corcept Therapeutics Inc for a number of months, seems to be less bullish one the $2.74 billion market cap company. The stock increased 1.70% or $0.4 during the last trading session, reaching $23.98. About 2.03 million shares traded or 10.44% up from the average. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since January 21, 2017 and is uptrending. It has outperformed by 108.11% the S&P500.

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on March, 5. They expect $0.19 EPS, up 375.00 % or $0.15 from last year’s $0.04 per share. CORT’s profit will be $21.69M for 31.55 P/E if the $0.19 EPS becomes a reality. After $0.11 actual EPS reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 72.73 % EPS growth.

Another recent and important Corcept Therapeutics Incorporated (NASDAQ:CORT) news was published by which published an article titled: “Corcept Therapeutics Incorporated (NASDAQ:CORT) Rises Over 5%” on December 27, 2017.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics has $25.0 highest and $14 lowest target. $20.75’s average target is -13.47% below currents $23.98 stock price. Corcept Therapeutics had 7 analyst reports since February 2, 2017 according to SRatingsIntel. Ladenburg Thalmann initiated Corcept Therapeutics Incorporated (NASDAQ:CORT) on Thursday, February 2 with “Buy” rating. The stock has “Buy” rating by Piper Jaffray on Thursday, August 24. As per Wednesday, October 11, the company rating was maintained by Piper Jaffray. On Friday, September 8 the stock rating was maintained by Piper Jaffray with “Buy”. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, November 3 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: